Development and implementation of large-scale quality control for the European bank for induced Pluripotent Stem Cells

O’Shea, Orla; Steeg, Rachel; Chapman, Charlotte; Mackintosh, Peter; Stacey, Glyn

doi:10.1016/j.scr.2020.101773

Cited by 36 publications

(34 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, STRs analysis is uninformative if used for specific cell culture modifications, such as co-culture of two cell types, analysis of differentiation stages within a single cell line, use of more cell subtypes derived from an individual. Similarly, techniques used for analysis of batch to batch variability, purity of cells, genome or proteome changes, as well as methods focused on a limited panel of biomarkers are not suitable for quality control in routine applications, because they are not informative and often are laborious and costly [30][31][32].…”

Section: Phenotype Shifts and Culture Adaptation In Hescsmentioning

confidence: 99%

Intact Cell Mass Spectrometry for Embryonic Stem Cell Biotyping

Vaňhara¹,

Moráň²,

Pečínka³

et al. 2021

Mass Spectrometry in Life Sciences and Clinical Laboratory

View full text Add to dashboard Cite

Stem cells represent a unique cell type that is capable of self-renewal and differentiation into somatic cell types. Since the derivation of human embryonic stem cells and induced pluripotent stem cells, enormous potential has been recognized for disease modeling, drug development and regenerative medicine. Both embryonic stem cells and induced pluripotent stem cells possess the ability to differentiate into all three germ layers, hence they are naturally prone to respond to various differentiation stimuli. These inherent cellular fluctuations, which can result in risky phenotypic instability, must be addressed prior to introduction of these cells to human medicine, since they represent one of the major biosafety obstacles in the development of bio-industrial or clinical-grade stem cell cultures. Therefore, there is an ongoing need for novel robust, feasible and sensitive methods for determination and confirmation of the otherwise identical cells status, as well as for the detection of hidden divergences from their optimal state. A method of choice can be the intact cell mass spectrometry. Here we show how it can be applied in routine quality control of embryonic stem cell cultures.

show abstract

Section: Phenotype Shifts and Culture Adaptation In Hescsmentioning

confidence: 99%

Intact Cell Mass Spectrometry for Embryonic Stem Cell Biotyping

Vaňhara¹,

Moráň²,

Pečínka³

et al. 2021

Mass Spectrometry in Life Sciences and Clinical Laboratory

View full text Add to dashboard Cite

show abstract

“…The cryopreservation and banking of hiPSC‐derived BCECs or respective progenitors will be a future trend for a standardized application of hiPSC‐derived BBB models in drug discovery. Several pan‐European, US, and Japanese strategies led to the establishment of sophisticated cell banks to address this need over the last decade and could serve as a source for high‐quality reference lines used for hiPSC‐derived BCEC progenitor generation (De Sousa et al., 2017; McKernan & Watt, 2013; O'Shea, Steeg, Chapman, Mackintosh, & Stacey, 2020).…”

Section: Current Technological Status In Hipsc‐derived Bbb Modelingmentioning

confidence: 99%

Human iPSC‐Derived Blood‐Brain Barrier Models: Valuable Tools for Preclinical Drug Discovery and Development?

Appelt‐Menzel

Oerter

Mathew

et al. 2020

CP Stem Cell Biology

View full text Add to dashboard Cite

Translating basic biological knowledge into applications remains a key issue for effectively tackling neurodegenerative, neuroinflammatory, or neuroendocrine disorders. Efficient delivery of therapeutics across the neuroprotective bloodbrain barrier (BBB) still poses a demanding challenge for drug development targeting central nervous system diseases. Validated in vitro models of the BBB could facilitate effective testing of drug candidates targeting the brain early in the drug discovery process during lead generation. We here review the potential of mono-or (isogenic) co-culture BBB models based on brain capillary endothelial cells (BCECs) derived from human-induced pluripotent stem cells (hiPSCs), and compare them to several available BBB in vitro models from primary human or non-human cells and to rodent in vivo models, as well as to classical and widely used barrier models [Caco-2, parallel artificial membrane permeability assay (PAMPA)]. In particular, we are discussing the features and predictivity of these models and how hiPSC-derived BBB models could impact future discovery and development of novel CNS-targeting therapeutics.

show abstract

“…To assess differentiation potential, we describe EB-based spontaneous differentiation. However, results from EBiSC indicate that hiPSCs that lack spontaneous differentiation still showed differentiation potential in all three germ layers (O'Shea, Steeg, Chapman, Mackintosh, & Stacey, 2020). Directed differentiation, on the contrary, might test very specific pathways, and the optimal assay to use is still under discussion (The International Stem Cell Initiative, 2018).…”

Section: Of 26mentioning

confidence: 99%

“…https://ebisc.org/ European Bank for Induced Pluripotent Stem Cells, a not-for-profit iPSC bank. Source for protocols, expert support, QC testing, and hiPSC lines (De Sousa et al, 2017;O'Shea et al, 2020).…”

Section: Author Contributionsmentioning

confidence: 99%

Cell Banking of hiPSCs: A Practical Guide to Cryopreservation and Quality Control in Basic Research

Shibamiya

Schulze

Krauß

et al. 2020

CP Stem Cell Biology

View full text Add to dashboard Cite

The reproducibility of stem cell research relies on the constant availability of quality-controlled cells. As the quality of human induced pluripotent stem cells (hiPSCs) can deteriorate in the course of a few passages, cell banking is key to achieve consistent results and low batch-to-batch variation. Here, we provide a cost-efficient route to generate master and working cell banks for basic research projects. In addition, we describe minimal protocols for quality assurance including tests for sterility, viability, pluripotency, and genetic integrity.

show abstract

Development and implementation of large-scale quality control for the European bank for induced Pluripotent Stem Cells

Cited by 36 publications

References 20 publications

Intact Cell Mass Spectrometry for Embryonic Stem Cell Biotyping

Intact Cell Mass Spectrometry for Embryonic Stem Cell Biotyping

Human iPSC‐Derived Blood‐Brain Barrier Models: Valuable Tools for Preclinical Drug Discovery and Development?

Cell Banking of hiPSCs: A Practical Guide to Cryopreservation and Quality Control in Basic Research

Contact Info

Product

Resources

About